Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Chaplin

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Plos One|March 20, 2010
Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceHenning Lauterbach, Ronny Kassub, Juliane Pätzold, et al.
Journal of Virology|December 16, 2011
The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulenceMarc Schweneker, Susanne Lukassen, Michaela Späth, et al.
The Journal of Clinical Investigation|April 10, 2008
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionChristofer Samuelsson, Jürgen Hausmann, Henning Lauterbach, et al.
Vaccine|June 23, 2009
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strainMark Suter, Christine Meisinger-Henschel, Maria Tzatzaris, et al.
Plos One|August 17, 2013
A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesSonia T Wennier, Kay Brinkmann, Charlotte Steinhäußer, et al.
Vaccine|February 15, 2020
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDSEdgar Turner Overton, Steven J Lawrence, Jack T Stapleton, et al.
Journal of Virology|June 12, 2010
Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesKaren Baur, Kay Brinkmann, Marc Schweneker, et al.
Immunology|December 28, 2017
CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient miceBarbara Bathke, Juliane Pätzold, Ronny Kassub, et al.
Vaccine|August 24, 2014
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitisFrank von Sonnenburg, Pamela Perona, Ulf Darsow, et al.
Frontiers in Immunology|July 1, 2022
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV InfectionKathrin Endt, Yvonne Wollmann, Jana Haug, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Plos One|March 20, 2010
Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceHenning Lauterbach, Ronny Kassub, Juliane Pätzold, et al.
Journal of Virology|December 16, 2011
The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulenceMarc Schweneker, Susanne Lukassen, Michaela Späth, et al.
The Journal of Clinical Investigation|April 10, 2008
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionChristofer Samuelsson, Jürgen Hausmann, Henning Lauterbach, et al.
Vaccine|June 23, 2009
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strainMark Suter, Christine Meisinger-Henschel, Maria Tzatzaris, et al.
Plos One|August 17, 2013
A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesSonia T Wennier, Kay Brinkmann, Charlotte Steinhäußer, et al.
Vaccine|February 15, 2020
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDSEdgar Turner Overton, Steven J Lawrence, Jack T Stapleton, et al.
Journal of Virology|June 12, 2010
Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesKaren Baur, Kay Brinkmann, Marc Schweneker, et al.
Immunology|December 28, 2017
CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient miceBarbara Bathke, Juliane Pätzold, Ronny Kassub, et al.
Vaccine|August 24, 2014
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitisFrank von Sonnenburg, Pamela Perona, Ulf Darsow, et al.
Frontiers in Immunology|July 1, 2022
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV InfectionKathrin Endt, Yvonne Wollmann, Jana Haug, et al.
Pageof 6